NasdaqGM - Delayed Quote
USD
Cronos Group Inc. (CRON)
2.6400
-0.0300
(-1.12%)
At close: May 1 at 4:00:01 PM EDT
2.6403
+0.0003
(+0.01%)
After hours: May 1 at 7:38:24 PM EDT
Trade CRON on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for CRON
- Previous Close
2.6700 - Open
2.6900 - Bid 2.6200 x 1400
- Ask 2.6600 x 1400
- Day's Range
2.6400 - 2.7300 - 52 Week Range
1.8100 - 3.4300 - Volume
863,409 - Avg. Volume
1,365,861 - Market Cap (intraday)
993.356M - Beta (5Y Monthly) 1.21
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date May 11, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.32
Recent News: CRON
View More
Performance Overview: CRON
Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
CRON
0.76%
S&P/TSX Composite index (^GSPTSE)
6.35%
1-Year Return
CRON
41.18%
S&P/TSX Composite index (^GSPTSE)
36.68%
3-Year Return
CRON
40.43%
S&P/TSX Composite index (^GSPTSE)
64.40%
5-Year Return
CRON
67.57%
S&P/TSX Composite index (^GSPTSE)
77.36%
Earnings Trends: CRON
View MoreAnalyst Insights: CRON
View MoreStatistics: CRON
View MoreValuation Measures
As of 5/1/2026
-
Market Cap
992.84M
-
Enterprise Value
162.55M
-
Trailing P/E
23.68
-
Forward P/E
30.86
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
6.91
-
Price/Book (mrq)
0.91
-
Enterprise Value/Revenue
1.11
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-6.45%
-
Return on Assets (ttm)
-0.90%
-
Return on Equity (ttm)
-0.26%
-
Revenue (ttm)
146.59M
-
Net Income Avi to Common (ttm)
-9.45M
-
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
-
Total Cash (mrq)
831.79M
-
Total Debt/Equity (mrq)
0.13%
-
Levered Free Cash Flow (ttm)
-51.22M
Compare To: CRON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
2.6400
-1.12%
Mkt Cap
993.356M
Industry
Drug Manufacturers—Specialty & Generic
3.4800
+1.16%
Mkt Cap
205.761M
Industry
Drug Manufacturers—Specialty & Generic
1.1300
+1.80%
Mkt Cap
507.461M
Industry
Drug Manufacturers—Specialty & Generic
3.3900
-3.69%
Mkt Cap
2.65B
Industry
Drug Manufacturers—Specialty & Generic
1.4200
+0.71%
Mkt Cap
199.704M
Industry
Drug Manufacturers—Specialty & Generic
6.16
-1.28%
Mkt Cap
736.762M
Industry
Drug Manufacturers—Specialty & Generic
8.01
-1.72%
Mkt Cap
1.813B
Industry
Drug Manufacturers—Specialty & Generic
1.0900
0.00%
Mkt Cap
391.891M
Industry
Drug Manufacturers—Specialty & Generic
9.59
-2.54%
Mkt Cap
1.844B
Industry
Drug Manufacturers—Specialty & Generic
1.3300
+2.31%
Mkt Cap
484.628M
Industry
Drug Manufacturers—Specialty & Generic
9.61
-0.26%
Mkt Cap
807.212M
Industry
Drug Manufacturers—Specialty & Generic
Company Insights: CRON
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: CRON
View More-
Cronos Group: Dropping Coverage
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
RatingPrice Target -
Cronos Earnings: Shares Rally on Improved Results but We Don't Think the Stock Offers Much Upside
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
RatingPrice Target -
Cannabis Sector Fares Terribly in 2024 US Elections, but Market Overreacts to Long-Term Impact
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
RatingPrice Target -
Cronos Remains Far From Critical Mass to Achieve Profitability; Cash Hoard Is Most of Its Value
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
RatingPrice Target
